In each of Verrica’s trials—known as CAMP-1 and CAMP-2 (Cantharidin Application in Molluscum Patients)—a clinically and statistically significant proportion of patients treated with VP-102 showed ...

On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial ...

Verrica Pharmaceuticals VRCA is preparing to release its quarterly earnings on Tuesday, 2025-08-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

As of August 2, 2023, the average one-year price target for Verrica Pharmaceuticals is 12.58. The forecasts range from a low of 10.10 to a high of $15.75. The average price target represents an ...

Shares of Verrica Pharmaceuticals Inc. (VRCA) have been struggling lately and have lost 15.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

Verrica Pharmaceuticals (NASDAQ:VRCA) added ~11% premarket Tuesday after the dermatology-focused drugmaker announced topline results from a mid-stage trial for its experimental therapy VP-315 targeted ...

SAN FRANCISCO, Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. (VRCA) investors that the firm is investigating potential legal claims relating to the ...

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) ...